All studies
Ongoing, recruitingTherapeutic confirmatory (Phase III)Interventional
A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal-Onset Seizures
At a glance
Status
Ongoing, recruiting
Phase
Therapeutic confirmatory (Phase III)
Sponsor
Xenon Pharmaceuticals Inc.
Enrolment target
168
Start
19 Apr 2023
What is this study about?
Proportion of subjects experiencing ≥50% reduction in monthly (28 days) focal seizure frequency from baseline through the DBP for XEN1101 versus placebo
Who may be eligible?
Age 18 Years to any · Sex: All
Locations (9)
- —Spain
- —Poland
- —Bulgaria
- —Italy
- —Germany
- —Ireland
- —Czechia
- —Latvia
- —Portugal
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.